Flora Growth Acquires CBD Brand Masaya

Flora Growth Corp. FLGC has entered into an agreement with a cell biologist, Dr. Annabelle Manalo-Morgan, Ph.D., to acquire her brand Masaya, together with its patent-pending CBD formulations. Created by Dr. Annabelle and backed by her research, Masaya’s formulations of pure, potent CBD oil are 100% THC-free and have a long track record of positive testimonials collected over years of use. Flora intends to distribute the brand and its formulations worldwide.

Masaya will become an owned Flora brand sold in the US and will be the first offering from Flora Life Sciences. In addition, it is expected that the original patent-pending formulation, Masaya Pure, will be used in Flora’s current clinical trials with the University of Manchester in the UK. The formulation is also in the process of being registered with the Colombian regulatory agency, INVIMA, as one of the first distribution steps beyond the US.

“We are excited to announce the acquisition of Masaya. The brand’s formulation was developed by Dr. Annabelle for her son and has since been used by thousands of consumers. Amplifying Dr. Annabelle and her son’s beautiful story and improving the well-being of people around the world is our aim,” Flora’s chairman and CEO Luis Merchan stated. “This acquisition allows us to deliver on our promise to invest in safe, thorough, cutting-edge scientific research that can bring meaningful change via an efficacious and accessible product offering for people worldwide.”

As a member of Flora’s board of directors and as the company’s scientific advisor, Dr. Annabelle is responsible for leading Flora’s global research initiatives, including Flora’s ongoing clinical trial on the use of cannabinoids with patients who have fibromyalgia in partnership with the University of Manchester in the UK. Those clinical trials are expected to expand into research on the use of cannabinoids for other medical indications in the UK, at Flora’s research facilities in Colombia, and in the US. It is anticipated that proceeds from the sale of Masaya products will contribute to the funding of this vital research.

Dr. Annabelle Manalo-Morgan's Story

After the birth of her son Macario in 2016, Dr. Annabelle endured watching him suffer from as many as 200 seizures per day which led doctors to remove 38 percent of his brain. Relentlessly, Dr. Annabelle searched for alternative solutions for Macario and eventually discovered CBD, which has helped Macario, now six, become a happy and thriving child.

“After my experience with my son Macario, I am very excited to bring Masaya to more consumers worldwide, to do my very best to help as many people as I can,” stated Dr. Annabelle, lead scientific advisor and director of Flora. “Both consumers and the global scientific community deserve more research and data on the science behind CBD, and I feel truly grateful to be working with the Flora team to help develop some of the highest-quality, scientifically vetted products in the world.”

Dr. Annabelle is a scientist, educator, author, mother of five, and a respected key opinion leader. She is a cell and developmental biologist with a doctorate from Vanderbilt University in Nashville, Tennessee, with a background in neuroscience from Georgetown University. She earned her Ph.D. in cell and developmental biology with a focus in cardio-oncology and has since become a philanthropist and entrepreneur focused on pharmaceutical innovation and clinical trial research in medical cannabis.

Photo by Jeff W on Unsplash

Related News

 

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: CannabisNewsPenny StocksMarketsDr. Annabelle Manalo-MorganLuis Merchan
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!
CCC-Oct-24-Banner-1

Click on the image for more info.

Cannabis rescheduling seems to be right around the corner

Want to understand what this means for the future of the industry?

Hear directly for top executives, investors and policymakers at the Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9. 

Get your tickets now before prices surge by following this link.